Journal of Antimicrobial Chemotherapy, Vol 40, 195-203, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
Y Kato, M Otsuki and T Nishino
BO-2727 is a new injectable carbapenem antibiotic with broad-spectrum,
potent antibacterial activity. The in-vitro and in-vivo antibacterial
activities of BO-2727 were compared with those of meropenem, imipenem and
biapenem. BO-2727 was four- to eight-fold more active in vitro than
meropenem, imipenem and biapenem against methicillin-resistant
Staphylococcus aureus, inhibiting more than 90% of clinical isolates at a
concentration of 12.5 mg/L. BO-2727 also showed superior activity against
Pseudomonas aeruginosa, and was two- to four-fold more active than imipenem
against imipenem-resistant strains. The antimicrobial activity of BO-2727
was influenced by the pH of the medium and inoculum size, in the same way
as meropenem and imipenem. In time-killing kinetic studies, BO-2727 showed
dose-dependent bactericidal activity against S. aureus, Escherichia coli
and P. aeruginosa. In a morphological study, BO-2727 induced spherical
forms in E. coli and bulging forms in P. aeruginosa. The affinity of
BO-2727 for E. coli (PBP 2) was about twice that of imipenem. BO-2727 also
had high affinities for P. aeruginosa penicillin-binding protein (PBPs) 2
and 3. The prophylactic efficacy of BO-2727 against Gram-positive and Gram-
negative bacterial systemic infections was similar to that of imipenem and
biapenem.
ORIGINAL ARTICLES
Antibacterial properties of BO-2727, a new carbapenem antibiotic
Department of Microbiology, Kyoto Pharmaceutical University, Japan.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. R. Edwards and M. J. Betts Carbapenems: the pinnacle of the {beta}-lactam antibiotics or room for improvement? J. Antimicrob. Chemother., January 1, 2000; 45(1): 1 - 4. [Full Text] [PDF] |
||||
